Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASND
Previous Symbol
CUSIPN/A
Phone45-7022-2244
Debt
Debt-to-Equity RatioN/A
Current Ratio9.87
Quick Ratio9.87
Price-To-Earnings
Trailing P/E Ratio-14.33
Forward P/E Ratio-14.62
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.80 million
Price / Sales1,440.70
Cash FlowN/A
Price / CashN/A
Book Value$5.82 per share
Price / Book10.60
Profitability
EPS (Most Recent Fiscal Year)($4.33)
Net Income$-140,040,000.00
Net Margins-17,641.85%
Return on Equity-49.69%
Return on Assets-45.56%
Miscellaneous
Employees137
Outstanding Shares42,030,000
Market Cap$2.66 billion
OptionableOptionable
Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions
What is Ascendis Pharma A/S's stock symbol?
Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."
How were Ascendis Pharma A/S's earnings last quarter?
Ascendis Pharma A/S (NASDAQ:ASND) released its quarterly earnings results on Wednesday, August, 29th. The biotechnology company reported ($0.66) EPS for the quarter, topping analysts' consensus estimates of ($1.03) by $0.37. The biotechnology company earned $0.02 million during the quarter, compared to analysts' expectations of $0.16 million. Ascendis Pharma A/S had a negative net margin of 17,641.85% and a negative return on equity of 49.69%. View Ascendis Pharma A/S's Earnings History.
When is Ascendis Pharma A/S's next earnings date?
What price target have analysts set for ASND?
9 brokers have issued 12-month target prices for Ascendis Pharma A/S's shares. Their predictions range from $60.00 to $88.00. On average, they expect Ascendis Pharma A/S's share price to reach $77.50 in the next year. This suggests a possible upside of 24.9% from the stock's current price. View Analyst Price Targets for Ascendis Pharma A/S.
What is the consensus analysts' recommendation for Ascendis Pharma A/S?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ascendis Pharma A/S.
Has Ascendis Pharma A/S been receiving favorable news coverage?
News headlines about ASND stock have trended somewhat positive on Tuesday, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ascendis Pharma A/S earned a news impact score of 1.5 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future.
Who are some of Ascendis Pharma A/S's key competitors?
Some companies that are related to Ascendis Pharma A/S include Bausch Health Companies (BHC), Genmab A/S (GNMSF), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Sarepta Therapeutics (SRPT), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Amarin (AMRN), SAGE Therapeutics (SAGE), Amneal Pharmaceuticals (AMRX), Nektar Therapeutics (NKTR), Alkermes (ALKS), Dr.Reddy's Laboratories (RDY) and Catalent (CTLT).
Who are Ascendis Pharma A/S's key executives?
Ascendis Pharma A/S's management team includes the folowing people:
- Michael Wolff Jensen, Chairman, SVP & General Counsel
- Jan Møller Mikkelsen, President, Chief Executive Officer & Director
- Neil T. Ringdahl, Chief Operating Officer
- Scott T. Smith, Chief Financial Officer & Senior Vice President
- Harald Rau, Chief Scientific Officer & Senior Vice President
When did Ascendis Pharma A/S IPO?
(ASND) raised $85 million in an initial public offering (IPO) on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.
Who are Ascendis Pharma A/S's major shareholders?
Ascendis Pharma A/S's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (9.88%), Alliancebernstein L.P. (1.70%), BlackRock Inc. (1.10%), First Manhattan Co. (0.65%), FIL Ltd (0.27%) and Acuta Capital Partners LLC (0.17%).
Which institutional investors are selling Ascendis Pharma A/S stock?
ASND stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, First Manhattan Co., Matisse Capital and Victory Capital Management Inc..
Which institutional investors are buying Ascendis Pharma A/S stock?
ASND stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, FIL Ltd, Fosun International Ltd, DekaBank Deutsche Girozentrale, BlackRock Inc., Alliancebernstein L.P., Alps Advisors Inc. and Wells Fargo & Company MN.
How do I buy shares of Ascendis Pharma A/S?
Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ascendis Pharma A/S's stock price today?
One share of ASND stock can currently be purchased for approximately $62.04.
How big of a company is Ascendis Pharma A/S?
Ascendis Pharma A/S has a market capitalization of $2.66 billion and generates $1.80 million in revenue each year. The biotechnology company earns $-140,040,000.00 in net income (profit) each year or ($4.33) on an earnings per share basis. Ascendis Pharma A/S employs 137 workers across the globe.
What is Ascendis Pharma A/S's official website?
How can I contact Ascendis Pharma A/S?
Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 5, HELLERUP G7, 2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]
MarketBeat Community Rating for Ascendis Pharma A/S (NASDAQ ASND)
MarketBeat's community ratings are surveys of what our community members think about Ascendis Pharma A/S and other stocks. Vote "Outperform" if you believe ASND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASND will underperform the S&P 500 over the long term. You may vote once every thirty days.
